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Tumors arising in the central nervous system are thought to originate from a sub-population of
cells named cancer stem cells (CSCs) or tumor initiating cells (TICs) that possess an immature
phenotype, combined with self-renewal and chemotherapy resistance capacity. Moreover, in the
last years, these cells have been identiﬁed in particular brain tumor niches fundamental for
supporting their characteristics. In this paper, we report studies from many authors demonstrating
that hypoxia or the so called “hypoxic niche” plays a crucial role in controlling CSC molecular and
phenotypic proﬁle. We recently investigated the relationship existing between Glioblastoma (GBM)
stem cells and their niche, deﬁning the theory of three-concentric layers model for GBM mass.
According to this model, GBM stem cells reside preferentially within the hypoxic core of the tumour
mass, while more differentiated cells are mainly localized along the peripheral and vascularized
part of the tumour. This GBM model provides explanation of the effects mediated by the tumour
microenvironment on the phenotypic and molecular regulation of GBM stem cells, describing their
spatial distribution in the tumor bulk. Moreover, we discuss the possible clinical implications of
the creation of this model for future GBM patient management and novel therapeutic strategies
development.
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1. HYPOXIC REGULATION OF NEURAL AND CANCER STEM CELLS
In vertebrate organisms, O2 is essential for life, acting as the central energy source in oxidative cell
metabolism [1]. However, the physiologically normoxic conditions for embryonic or adults human cells
generally fall in the 2–9% O2 (14.4–64.8mmHg) range [2], substantially lower than the 20.8% O2
(156mmHg, at sea level) in the air we breathe. Tissue oxygen tension (pO2) values are conserved among
mammalian species central nervous system (CNS) but vary along diverse brain regions. Since brain is one
of the most metabolically active tissues in the body, pO2 levels are tightly regulated and, in particular, these
values range from as low as 0.55% (4.1mmHg) in the midbrain to 8.0% (60mmHg) in the pia [3]. This
heterogeneity allows conceiving that cells adjacent to the arterial inﬂow (high pO2) display characteristics
and capacities that are different from those located at the venous end (low pO2).
The role of lowered oxygen in the regulation of neural precursors proliferation and differentiation
has been described by our group in the last years [4]. We demonstrated that 20% oxygen promotes CNS
precursors mitotic arrest and terminal differentiation to an astrocytic fate, with an increase in the number
of p21 positive cells, a cyclin-dependent kinase inhibitor induced by p53, and a direct effector of mitotic
arrest. Conversely, lowered oxygen increases proliferation and viability of CD133+ neural stem cells and
oligodendrocyte progenitors [4]. Accordingly, a previous work from Smith and colleagues underlined the
role of redox state as a central modulator of the balancebetween self-renewal and differentiation in dividing
glial precursor cells [5]. They showed that treatment of dividing murine oligodendrocyte precursor cells
(OPCs) with prooxidant drugs was associated with diminished progenitor division and increased number of
differentiated cells. In contrast, OPCs treated with antioxidant molecules exhibited enhanced proliferation,
self-renewal, and a marked reduction in oligodendrocyte generation [5]. Besides maintaining stemness and
self-renewal of neural precursors, low pO2 (3–5%) also promotes generation of speciﬁc neural lineages.
Culture of rat neural crest stem cells in low O2 promotes their survival and differentiation into tyrosine
hydroxylase (TH)
￿ sympathoadrenal cells or TH
￿ dopaminergic neurons [6–9]. Thus, self-renewal and
differentiation capacity may depend on the cell type and the percentage of oxygen.
Disruption of the regulatory mechanism that controls self-renewal is reliably involved in the genesis
of cancer initiating stem-like cells [10]. This is probably what happens in the human brain where neo-
genesis of mature cells persists throughout adult life within discrete brain regions: the dentate gyrus of the
hippocampus and the subventricular zone of the forebrain lateral ventricles [11], both regions characterized
by the presenceof quiescentstem cells and mitotically active progenitor cells. These cell populations might
function as a source of cells for transformation, potentially giving rise to CSCs. The ﬁrst evidence of
the presence of cells with stem-like characteristics in human brain tumours was reported by Ignatova and
coworkers,who isolated clonogenicneurosphere-formingprecursors from postsurgery specimensof human
GBM and medulloblastoma tumors [12]. These stem-like cells expressed both neuronal and astroglial
markers of differentiation, together with several key determinants of neural stem cell phenotype. These
ﬁndings conﬁrmed that brain tumours contain transformed, undifferentiated neural cells that respond to the
same factors that activate adult neural stem cells and indicate that these tumour-initiating cells have the
ability to self-renew, proliferate, and express typical markers of stem cells, such as the cell surface marker
CD133 [13]. One aspect of the microenvironment that differs in normal versus tumor tissue is O2 tension.
In fact, in solid tumors, O2 tensions can range from physiological 2.5%–5.3% levels to pathological values
below 0.1% in necrotic regions [14].
A milestone in understandingoxygen physiologywas the identiﬁcation in 1995 by Wang et al. of the
hypoxiainduciblefactor(HIF) transcriptionalcomplex[15], whichis akeyregulatorysystemofresponseto
hypoxiaatbothlocal andsystemiclevels.RecentevidenceshowsthatHIF-1α is alsooverexpressedinmany
human cancers and has been associated with increased patient mortality [16–22]. Moreover, overactivity of
HIF-1α has been implicated in tumor progression [16, 23–25]. At present, it is considered that increased
HIF-1α expression in cancer is caused by intratumoural hypoxia [26]. Indeed, robust tumour growth
requires the presence of a local vascular network that supplies both oxygen and nutrients to tumour cells.
However, a highly proliferating mass of tumour cells develops faster than the vasculature, and tumour cells
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rapidly meet up with a poorly and/or aberrantly vascularized microenvironment deﬁcient in oxygen, that is,
hypoxic. Blood capillaries carry oxygen to tissues, but since oxygen has a diffusion limit, its concentration
decreases as the distance from capillaries increases. Microscopic examination of solid tumours reveals the
presence of expanding tumour cells in proximity to capillaries and central portion of necrotic regions. This
gradient of cell viability parallels that of a decreasing gradient of oxygen, which is accompanied by an
increase in HIF-1α levels, a decrease in the extracellular pH, and an induction of resistance to radio- and
chemotherapy [27]. Given these points, we can assume that HIF-1α correlates with cancer aggressiveness
and progression. According to the hypoxic tumour mass model, there are ﬁve main mechanisms by which
enhancement of HIF-1α levels may occur in cancer: (1) cancer cells have a reduced O2 metabolism via
oxphos and an increased O2 metabolism via ROS generation, two situations that can activate HIF-1α
and frequently observed in cancer [28]; (2) cancer cells depend on glycolysis for keeping adequate ATP
levels and glycolysis activation required an increase in HIF-1α activity [29]; (3) cancer cells seem to have
increased levels of H2O2, which is known to stabilize HIF-1α [30]; (4) cancers display increased HIF-
1α levels because of genetic alterations in the pathways responsible for HIF-1α synthesis and degradation
[26, 31]; (5) HIF-1α stabilization is driven by low pO2 (low or absent vascularization) in solid tumors [32].
Many studies have been delineating the relationship of HIF-1α signalling with a series of other
pathways possibly involved in tumor progression. Gustafsson and coworkers showed direct correlation
between Notch intracellular domain (NICD) and HIF-1α demonstrating for the ﬁrst time that hypoxia
increases the stability of NICD through a direct interaction with the N-terminal region of HIF-1α, thus
activating Notch signalling and maintaining cells in an undifferentiated state [33]. Recently, Land and
colleagues demonstrated the involvement of HIF-1α also in the Mammalian target of rapamycin (mTOR)
signalling pathway [34]. mTOR positively enhances levels of HIF-1α-mediated transcription during
conditions that favoured HIF-1α stabilization, that is, hypoxia. Moreover, our group previously showed a
correlation between hypoxia and BMP pathway modulation [4]. We observed that human neural precursors
derived from SVZ, when maintained under hypoxia (5% O2), are less sensitive to BMP treatment in vitro,
compared with cells maintained at 20% O2. Given this, we hypothesized that oxygen could regulate BMP
signalling at multiple steps, including SMAD activation and transcriptional induction of target genes such
as Id1. A subsequent work from our group showed a counteracting effect of HIF-1α and BMP signalling
r e g u l a t i o ni nG B M[ 35]. Taken together, all these aspects show a marked involvement of hypoxia and HIF-
1α in regulating not only physiologicalneural stem cells but also cancerprogression and CSC maintenance.
2. THE THREE-LAYER CONCENTRIC MODEL OF GLIOBLASTOMA
In light of the pivotal role of the niche in controlling fate determination of normal stem cells, it has been
suggested the existence of a CSC niche with the ability of modulating phenotypeof the self-renewing/more
immature tumor cell population[36]. In the effort to investigate the distribution of different tumor cell types
within GBM tumor, we recently formulated the hypothesis of a multilayer model of GBM mass. GBM
is the most frequent and most malignant brain cancer in adults [37], and despite the progress in deﬁning
the molecular characteristics of gliomas and the effort in formulating new therapeutic approaches, only
marginal improvements have been reported for patients outcome [38]. GBM are highly proliferative and
heterogeneous tumors and their morphology shows a great variety in a given patient, and from patient to
patient [39]. Moreover, GBMs frequently display areas of necrosis that occurs in avascularlow-oxygenated
regions, and cells residing in the tumor bulk could bear different grades of differentiation [40]. Since
the ﬁnding of a subpopulation of immature cells with stem-like properties in many types of solid tumors
including GBM, that have been pointed as responsible for tumor onset and relapse [41, 42], we and many
other researchers are trying to elucidate the relationship between differential tumor microenvironments
and CSCs regulation [4, 36, 43–48]. Moreover, increasing evidence suggests that different nontumor cells
and factors derived from the tumor microenvironment are necessary to regulate CSCs. Carcinoma-derived
prostate ﬁbroblasts, showing distinct molecular features from those that reside in normal tissues, were able
to induce tumor progression in prostate epithelial cells [49, 50]. Moreover, specialized microenvironments
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appear to be required for the engraftment of leukemic stem cells. Acute myeloid leukaemia cells have been
shown to stick to extracellular matrix components, and CD44 has been reported to be fundamental for
this process [51–53]. Also endothelial cells (ECs) seem to play a crucial function in creating a speciﬁc
niche for CSCs residing in solid tumors, in particular of brain cancers [44, 54]. Since Calabrese and
colleagues showed that putative brain tumor stem cells, expressing CD133 and Nestin, were localized
near the capillaries and interacted with them in vitro, it is conceivable to hypothesize that CSCs require
signals derived from the heterotypic interaction between endothelial cells (or other cellular entities) and the
tumor epithelial compartment possibly involving Notch signalling, as described also for T-ALL xenografts
[44, 55, 56]. In particular, ECs release soluble factors such as BDNF [57], PEDF [58], and VEGF-C [59]
that enhance glioma CSCs proliferation and stemness maintenance. Conﬁrming this hypothesis, a recent
work demonstrated that the presence of immature, nestin-expressingcells in the perivascularniche is driven
by activated Notch signaling in brain tumour precursor cells. This activation is mediated by eNOS enzyme
[60] and by DLL4, a notch ligand overexpressedin ECs [61].
In this context of differential microenvironmental stimuli, possibly involved in the homing and
regulation of CSCs, hypoxia seems to play a fundamental role in sustaining CSCs phenotype and
aggressiveness, as described in the previous paragraph. One of the ﬁrst attempts to clarify stem cells
distribution in relation to tissue hypoxic gradients was discussed by Chow and coauthors, who developed a
mathematical framework to evaluate pO2 distributions in the bone marrow hematopoietic compartment,
considering the complex cellular architectures, cell layers, and clustering arrangements that compose
bone marrow. They found that hematopoietic stem cells are located in regions with very low pO2 levels
[62, 63], as previously suggested by Cipolleschi et al. in 1993 [64]. Subsequently, other studies conﬁrmed
this mathematical hypothesis describing the correlation between haematopoietic stem cell phenotype and
regional hypoxia [65]. Authors showed that speciﬁc regions in the bone marrow with low blood perfusion
levels contained the highest concentration of hematopoietic precursors and stem cells, according to an
oxygen perfusion gradient [65]. HIF proteins via their stabilization under regionally deﬁned hypoxia may
thus serve as upstream regulators of many key processes involved in stem cell function.
The ﬁrst evidence of a determined spatial distribution of different stem cells in brain tumors has
been reported by Piccirillo et al. who described the existence of diverse subpopulations of CSCs, sharing
common progenitors, albeit being different at the genetic and functional levels in different locations of
brain tumors [48]. In this study, cells were obtained from biopsies dissected from the core of the GBM
mass and from the periphery of the tumor. These CSC populations displayed different growth kinetics,
clonogenic index and tumor-initiating ability, suggesting a more differentiated phenotype for GBM cells
derived from the peripheral regions of the mass [48]. In this study, authors correlated diverse functional
behaviourwith distinct sets ofgenetic abnormalities,eventhoughit is conceivableto hypothesizethat tumor
tissueoxygenationlevelscouldalso cooperateto inducedifferentcellphenotypesin multiple compartments,
as previouslyshown[36, 66–70]. Nonetheless,previousstudies suggestedthat hypoxiais linked to genomic
instability and p53 suppression [71, 72], thus raising the possibility of a causative relationship between
biopsy collection site and genomic alterations described in this study [48]. In a recent study, tumor biopsies
were collected from locations displaying differential levels of hypoxia in the tumor bulk. Samples were
selected from within the tumor and in nonfunctional areas from peritumor and surrounding host tissue
according to T1 contrast-weighed volumetric MRI [73]. Authors suggest that speciﬁc regional hypoxia is
strictly correlated to the induction of a differential proinﬂammatory signature in GBM stem cells [73].
Our group developed a tridimensional model of the GBM tumor mass based on the differential
molecularand phenotypiccellular identities distributed along the hypoxicgradient in GBM tumors [74, 75].
In this study,we identiﬁedthree layers in the GBM massandclassiﬁedthem as core(necrotic), intermediate
layer,andperipheral/hyper-vascularizedtumorarea.Sampleswerecollectedfromeachofthethreelayersby
means of image-guided surgery. The intermediate area has been consideredas the transition area in between
the inner core and the peripheral area (contrast enhancing ring at MRI after gadolinium administration)
(Figure 1). By exploiting this procedure, we were able to reproducibly collect GBM samples with distinct
phenotypes and functional characteristics according to the hypoxic gradient in the GBM tumor mass. Since
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FIGURE 1: The three GBM layers identiﬁed by MRI analysis. Through radiological imaging we identiﬁed
three layers in the GBM mass, classiﬁed as core, intermediate layer, and peripheral/hyper-vascularized
tumor area. The intermediate area has been considered as the transition area in between the inner core
and the peripheral layer (contrast enhancing ring). The surgical procedure was monitored by intraoperative
imaging (neuronavigational setting). The neurosurgical resection of the peripheral regions had been done
along the tumor/normal brain interface with the effort to avoid normal cells to be included in the specimen.
necrotic areas of solid tumors display a low-oxygenated microenvironment and cells lining necrotic tissues
are exposed to milder hypoxia, it is conceivable to hypothesize a model in which more necrotic areas
of GBM tissues are characterized by strong hypoxia and surrounded by less hypoxic cancer cells [14].
Oppositely cells from the contrast enhancing ring, supposed to be the most vascularized tumor layer, are
exposed to the highest oxygen tension in the GBM tumor bulk. Although we did not directly measured
oxygen tensions in the diverse location from which biopsies were collected, we found hypoxia markers
such as HIF-1α and its downstream targets CAIX and VEGF to be more abundant in the inner portions
of the tumor mass, dramatically decreasing their expression in areas supposed to be more oxygenated
[74]( Figure 2). Given the assumption that hypoxia promotes a stem cell phenotype of brain tumor cells
[56, 70, 76–78], our data showed that more immature cells (expressing Nestin) were found in the inner core
and intermediate layers, whereas more differentiated (as veriﬁed with neuronal and glial markers) were
distributed at the periphery of the tumor [74, 75]( Figure 2). Despite the description of vascular stem cell
niche for GBM [44], we found that CD133+ cancer stem cells were localized in the inner portions of the
GBM mass,corroborating the hypothesizedexistenceof a different stem cellniche in which cancercells are
exposed to very low levels of oxygen and activate, through HIF-1α stabilization, a transcriptional program
able to modulate the balance between proliferation and quiescence, aggressiveness, resistance to therapy,
and invasiveness [26, 74, 79–81]. As a conﬁrm, Seidel and colleagues reported that GBM-derived stem
cells, identiﬁed using the side population (SP) approach and conﬁrmed by CD133 staining, were highly
enriched in both vascular and necrotic/hypoxic niches within the tumor bulk [82]. Moreover, they showed
that hypoxia promoted the expression of a stem cell signature through HIF-2α-mediated upregulation of
Oct-4 [82]. In 2006, Shinya Yamanaka’s group demonstrated that the transcription factors Oct4, Sox2,
Klf4, and c-Myc can convert a differentiated cell back to pluripotency over the course of a few weeks,
thus reprogramming them into induced pluripotent stem (iPS) cells [83]. Thus hypoxia-dependent Oct-4
overexpression could play a fundamental role in determining tumor cell characteristics by pushing back
more differentiated cells to a stem-like phenotype.
Although severaldata suggesting that more immature cells residing in the inner portions of the GBM
mass could potentially be CSCs, further experiments will be needed to clearly characterize the functional
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FIGURE 2: Phenotypic and molecular characteristics of the three concentric layers model of GBM.
Inner portions of tumor mass display more immature cancer cells (Nestin+) and account for the highest
percentages of cancer stem cells identiﬁed by CD133 staining. This identiﬁed stem cell population is
resistant to alkylating agents-based chemotherapy in vitro. Peripheral GBM cells show a more differentiated
phenotype (GFAP+, β-III-tubulin+) with low levels or absence of CD133+ cells. These peripheral tumor cells
are highly sensitive to Temozolomide.
identity of these cells. In particular, according to the most recent deﬁnitions, a tumor cell can be considered
as CSC after its tumorigenic potential has been evaluated in serial xenotransplantation experiments in
mice. CD133+ cells derived from the different GBM layers must be tested for their tumorigenic potential
before we can ﬁnally deﬁne these cells as CSC. Many authors described CD133 as a marker for the
identiﬁcation of GBM initiating cells and that CD133+ cells are able to generate tumors in mice [84, 85].
Moreover, high levels of CD133 have been correlated to GBM tumor progression and dissemination [86].
Nevertheless,otherstudiesreportedthatalsotheCD133− subpopulationhasatumorigenicpotential,raising
some concerns about the real tumorigenic cell fraction of these tumors [87–90]. Even though we did not
evaluate the tumor formation ability of GBM cells from different layers, cells located in the core and the
intermediated layer show low levels of differentiation markers and high expression of Nestin [74], that
has been reported to enhance the tumorigenic potential of GBM cells [91], suggesting a more aggressive
phenotype of these cells.
This issue does not prevent us from pointing some remarks about the inﬂuence of tumor micro-
environment in the regulation of CSCs. These data, resumed here from different studies, suggest that
CSCs are located in speciﬁc microenvironments within the tumor, reminiscent of the stem cell niches
described for neural stem cells [92, 93], and that tumors sustain their growth by the generation of new
or expansionof preexisting niches, which support the maintenance of an undifferentiated phenotype. Given
the important relation between stem cells and their niches [44, 74, 82], and the recent new deﬁnition of
stemness described by Zipori, who suggested that stemness might be “a transient and reversible trait that
almost anycell can assumegiventhe correct niche”[94], we can argue that determining the precise location
in which CSCs reside, besides deﬁning their molecular characteristics, might help generating a new set of
speciﬁcmicroenvironmentalmoleculartargets.Inthis context,thedeﬁnition ofa multilayer modelfor GBM
opens new questions on the right strategies to be developed in the future for GBM patients’ management.
In the next paragraph, therapeutic and surgical consequences of the generation of such a model will be
discussed.
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3. CLINICAL IMPLICATIONS
One of the main pitfalls in cancer treatment is the hypoxia-associated resistance to photon radiotherapy,
causative of tumour progression and relapse. The presence of molecular oxygen increases DNA damage
through the formation of oxygen-free radicals, which occurs primarily after the interaction of radiation with
intracellularwater. Thus,becauseofthis so-called“oxygenenhancementeffect,”theradiationdoserequired
to achieve the same biologic effect is three times higher in the absence of oxygen than in the presence of
normal oxygen levels. Evidence suggests that hypoxia-induced proteome and genome changes may also
have a substantial impact on radioresistance by increasing the levels of heat shock proteins or by increasing
the number of cells in a tumour with diminished apoptotic potential or increased proliferation rate, both of
which have been linked to radioresistance [95].
Clinical implications arising from the three layers model of CSCs distribution in GBM could
be remarkable, ﬁrst of all, for diagnostic purposes. Since GBM displays different phenotypic patterns
and molecular signalling activation in distinct regions (layers) of the tumor mass [74], the pathological
characterization can be inﬂuenced by the site of sample collected by the surgeon throughout the tumor. For
example, MGMT protein has been found differentially expressed among the three layers [74], and both
MGMT protein expression and promoter methylation status are considered important prognostic factors
[96, 97]. This issue is fundamental because in the modern neuro-oncological setting, several diagnostic and
prognostic markers [98] are commonly analyzed to predict tumor grade and the consequential therapeutic
approach [99, 100]. In addition, biomarkers are pivotal in the selection of glioma patients for their recruit-
ment into clinical trials [101]. In this sense, site of the tumour sample collection could represent a remark-
able bias for both selection and stratiﬁcation of patients, as previously addressed by other authors [102].
The therapeutic implications of the three-layer model are more difﬁcult to analyse because of the
absence of clinical studies and the involvement of different variables. In this context, we are authorized to
make only somereﬂections,whereasfurther studiesare undoubtedlyneededto conﬁrm nextconsiderations.
However, the three-layer model could potentially have some interesting implications for both surgical and
oncological settings. In fact, being putative CSCs mainly located in the core of GBM [74, 75], surgeon
should achieve the complete removal of central region of tumor drastically reducing in this way the
residual CSC population, which is considered the major responsible of resistance requiring supplementary
treatments [103]. This assertion is apparently in contrast with the clinical experience of neurosurgeons that
reports very high percentages of GBM recurrence, even after total removal of the primary tumor mass.
There could be at least three different explanations for this phenomenon. First, we measured the presence
of putative CSCs (CD133+ GBM cells), even if in very low numbers, also in the more peripheral regions of
the tumor [74, 75]. Second, hypoxia and HIF-1α have been reported to enhance the migration properties of
cancercells by promoting metalloproteinaseexpressionand migration-associatedreceptorssuch as CXCR4
[104, 105]. Moreover, hypoxia has been described to regulate CXCR4-dependent cell migration also in
lymphomamodels[106]. Itis conceivableto hypothesizethathypoxiaincreasesGBMcellmigratory ability,
thus inducing cells residing in the core of the tumor to migrate through the above-described layers and
potentially invade normal brain tissues outside of the GBM mass or form the scant CD133+ cell population
of the peripheral layers [74]. Third, neural stem cells migrate from the subventricular zone or the dentate
gyrus of the hippocampus to their ﬁnal destination during the differentiation process in the developing and
adult brain [107]. There could be the possibility that CSCs conserve their migration ability without being
able to correctly differentiate toward a less proliferative and aggressive phenotype, inﬁltrating surrounding
normal brain tissues.
During GBM management, surgery is followed by radiotherapy and concomitant alkylating agents-
based chemotherapy that could be virtually more effective against a tumoural residue possibly depleted
of CSCs. A further consideration can be done about loco-regional therapies, which are treatments that
surgeons can carry out directly in the surgical cave after tumour removal. This is the case of BCNU wafers
that are a worldwide approved treatment for both newly diagnosed and recurrent high-grade gliomas [108].
They are constituted by degradable biopolymer wafers impregnated of Carmustine (an alkylating agent)
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that is released over few weeks in the surgical cave [109]. Wafers are implanted in the surgical cave after
tumour removal,and they are positioned in tight contactwith the brain surface inﬁltrated by tumour.Whena
complete removal of central core of tumour has been achieved, locoregional therapy such as BCNU wafers
could be more effective against a limited CSC population. Finally, current chemotherapy points to tailored
treatment.Inthissense,thesetypesofresidualtumourcellsshouldbetargetedbysupplementarytreatments.
Whenalarge tumourexeresisis notachievablefordifferentreasons(suchasproximity to functionalcortical
areas and inﬁltration of major vessels), the residual tumour might be targeted by using prodifferentiating
treatments together with conventional therapies, thus affecting CSC phenotype and aggressiveness.
ACKNOWLEDGMENTS
This work was supported by Fondazione Citt` a della Speranza and by funds from the Italian Association for
the Fight against Neuroblastoma (Pensiero Project), the Italian Association AIRC (Interregional pediatric
project grant), and University of Padova, Young Investigators Grant.
REFERENCES
[1] J. Raymond and D. Segre, “The effect of oxygen on biochemical networks and the evolution of complex life,”
Science, vol. 311, no. 5768, pp. 1764–1767,2006.
[2] M. C. Simon and B. Keith, “The role of oxygen availability in embryonic development and stem cell function,”
Nature Reviews Molecular Cell Biology, vol. 9, no. 4, pp. 285–296, 2008.
[3] R. D. Hoge and G. B. Pike, “Oxidative metabolism and the detection of neuronal activation via imaging,”
Journal of Chemical Neuroanatomy, vol. 22, no. 1-2, pp. 43–52, 2001.
[4] F. Pistollato, H. L. Chen, P. H. Schwartz, G. Basso, and D. M. Panchision, “Oxygen tension controls the
expansion of human CNS precursors and the generation of astrocytes and oligodendrocytes,” Molecular and
Cellular Neuroscience, vol. 35, no. 3, pp. 424–435, 2007.
[5] J. Smith, E. Ladi, M. Mayer-Proschel,and M. Noble, “Redoxstate is a central modulatorof the balancebetween
self-renewal and differentiation in a dividing glial precursor cell,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 97, no. 18, pp. 10032–10037,2000.
[6] S. J. Morrison, M. Csete, A. K. Groves, W. Melega, B. Wold, and D. J. Anderson, “Culture in reduced levels
of oxygen promotes clonogenic sympathoadrenaldifferentiation by isolated neural crest stem cells,” Journal of
Neuroscience, vol. 20, no. 19, pp. 7370–7376,2000.
[7] A. Storch, G. Paul, M. Csete et al., “Long-term proliferation and dopaminergic differentiation of human
mesencephalic neural precursor cells,” Experimental Neurology, vol. 170, no. 2, pp. 317–325, 2001.
[8] L. Studer,M. Csete, S. H. Lee et al., “Enhancedproliferation,survival,and dopaminergicdifferentiationof CNS
precursors in lowered oxygen,” Journal of Neuroscience, vol. 20, no. 19, pp. 7377–7383,2000.
[9] J. Milosevic, S. C. Schwarz, K. Krohn, M. Poppe, A. Storch, and J. Schwarz, “Low atmospheric oxygen avoids
maturation, senescence and cell death of murine mesencephalic neural precursors,” Journal of Neurochemistry,
vol. 92, no. 4, pp. 718–729, 2005.
[10] A. L. Vescovi, R. Galli, and B. A. Reynolds, “Brain tumour stem cells,” Nature Reviews Cancer, vol. 6, no. 6,
pp. 425–436, 2006.
[11] P. S. Eriksson, E. Perﬁlieva, T. Bjork-Eriksson et al., “Neurogenesis in the adult human hippocampus,” Nature
Medicine, vol. 4, no. 11, pp. 1313–1317,1998.
[12] T. N. Ignatova,V. G. Kukekov,E. D. Laywell, O. N. Suslov, F. D. Vrionis, and D. A. Steindler, “Human cortical
glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro,” GLIA, vol. 39,
no. 3, pp. 193–206, 2002.
[13] S. Tamaki, K. Eckert, D. He et al., “Engraftment of sorted/expanded human central nervous system stem cells
from fetal brain,” Journal of Neuroscience Research, vol. 69, no. 6, pp. 976–986, 2002.
[14] A. S. E. Ljungkvist, J. Bussink, J. H. A. M. Kaanders, and A. J. van der Kogel, “Dynamics of tumor hypoxia
measured with bioreductive hypoxic cell markers,” Radiation Research, vol. 167, no. 2, pp. 127–145, 2007.
1836TheScientiﬁcWorldJOURNAL (2011) 11, 1829–1841
[15] G. L. Wang, B. H. Jiang, E. A. Rue, and G. L. Semenza, “Hypoxia-inducible factor 1 is a basic-helix-loop-
helix-PAS heterodimer regulated by cellular O2 tension,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 92, no. 12, pp. 5510–5514,1995.
[16] P. Birner, B. Gatterbauer, G. Oberhuber et al., “Expression of hypoxia-inducible factor-1α in oligoden-
drogliomas: its impact on prognosis and on neoangiogenesis,” Cancer, vol. 92, no. 1, pp. 165–171, 2001.
[17] A. W. Eckert, A. Schutze, M. H. W. Lautner,H. Taubert, J. Schubert,andU. Bilkenroth,“HIF-1α is a prognostic
marker in oral squamous cell carcinomas,” International Journal of Biological Markers, vol. 25, no. 2, pp. 87–
92, 2010.
[18] J. R. Flynn, L. Wang, D. L. Gillespie et al., “Hypoxia-regulated protein expression, patient characteristics, and
preoperative imaging as predictors of survival in adults with glioblastoma multiforme,” Cancer, vol. 113, no. 5,
pp. 1032–1042,2008.
[19] X. Liang, M. Zheng, J. Jiang, G. Zhu, J. Yang, and Y. Tang, “Hypoxia-inducible factor-1 alpha, in association
with TWIST2 and SNIP1, is a critical prognostic factor in patients with tongue squamous cell carcinoma,” Oral
Oncology, vol. 47, pp. 92–97, 2010.
[20] M. Z. Qiu, B. Han, H. Y. Luo et al., “Expressions of hypoxia-inducible factor-1α and hexokinase-II in gastric
adenocarcinoma: the impact on prognosis and correlation to clinicopathologic features,” Tumor Biology,v o l .
32, pp. 159–166, 2010.
[21] L. M. S. Seeber, N. Horree, P. van der Groep, E. van der Wall, R. H. M. Verheijen, and P. J. van Diest,
“Necrosis related HIF-1α expression predicts prognosis in patients with endometrioid endometrial carcinoma,”
BMC Cancer, vol. 10, article 307, 2010.
[22] J.Szkandera,G.Knechtel,M.Stotzetal.,“Associationofhypoxia-induciblefactor1-alphagenepolymorphisms
and colorectal cancer prognosis,” Anticancer Research, vol. 30, no. 6, pp. 2393–2397,2010.
[23] D. L. Gillespie, K. Whang, B. T. Ragel, J. R. Flynn, D. A. Kelly, and R. L. Jensen, “Silencing of hypoxia
inducible factor-1α by RNA interference attenuates human glioma cell growth in vivo,” Clinical Cancer
Research, vol. 13, no. 8, pp. 2441–2448,2007.
[24] L. Holmquist-Mengelbier, E. Fredlund, T. Lofstedt et al., “Recruitment of HIF-1α and HIF-2α to common
target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype,” Cancer
Cell, vol. 10, no. 5, pp. 413–423, 2006.
[25] G. L. Semenza, “Involvementof hypoxia-induciblefactor 1 in human cancer,”Internal Medicine, vol. 41, no. 2,
pp. 79–83, 2002.
[26] G. L. Semenza,“TargetingHIF-1forcancertherapy,”Nature ReviewsCancer, vol.3, no.10,pp.721–732,2003.
[27] P. Vaupel, “The role of hypoxia-induced factors in tumor progression,” Oncologist, vol. 9, no. 5, pp. 10–17,
2004.
[28] M. L´ opez-L´ azaro, “Does hypoxia really control tumor growth?” Cellular Oncology, vol. 28, no. 5-6, pp. 327–
329, 2006.
[29] R. H. Xu, H. Pelicano, Y. Zhouet al., “Inhibitionof glycolysis in cancer cells: a novelstrategy to overcomedrug
resistance associated with mitochondrial respiratory defect and hypoxia,” Cancer Research, vol. 65, no. 2, pp.
613–621, 2005.
[30] N. S. Chandel, D. S. McClintock, C. E. Feliciano et al., “Reactive oxygen species generated at mitochondrial
complex III stabilize hypoxia-inducible factor-1α during hypoxia: a mechanism of O2 sensing,” Journal of
Biological Chemistry, vol. 275, no. 33, pp. 25130–25138,2000.
[31] G. L. Semenza,“Hypoxia-induciblefactor 1 and cancerpathogenesis,”IUBMB Life, vol. 60,no. 9, pp. 591–597,
2008.
[32] P. H. Maxwell, G. U. Dachs, J. M. Gleadle et al., “Hypoxia-inducible factor-1 modulates gene expression in
solid tumors and inﬂuences both angiogenesis and tumor growth,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 94, no. 15, pp. 8104–8109,1997.
[33] M. V. Gustafsson,X. Zheng,T.Pereira etal.,“HypoxiarequiresNotchsignalingtomaintainthe undifferentiated
cell state,” Developmental Cell, vol. 9, no. 5, pp. 617–628, 2005.
[34] S. C. Land and A. R. Tee, “Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin
(mTOR) via an mTOR signaling motif,” Journal of Biological Chemistry, vol. 282, no. 28, pp. 20534–20543,
2007.
1837TheScientiﬁcWorldJOURNAL (2011) 11, 1829–1841
[35] F. Pistollato, H. L. Chen, B. R. Rood et al., “Hypoxia and HIF1α repress the differentiative effects of BMPs in
high-grade glioma,” Stem Cells, vol. 27, no. 1, pp. 7–17, 2009.
[36] J. B. Sneddon and Z. Werb, “Location, location, location: the cancer stem cell niche,” Cell Stem Cell, vol. 1, no.
6, pp. 607–611, 2007.
[37] T.Denysenko,L.Gennero,M. A.Rooset al.,“Glioblastomacancerstemcells: heterogeneity,microenvironment
and related therapeutic strategies,” Cell Biochemistry and Function, vol. 28, no. 5, pp. 343–351, 2010.
[38] R. Stupp, W. P. Mason, M. J. van Den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005.
[39] M. Hassler, S. Seidl, B. Fazeny-Doerner et al., “Diversity of cytogenetic and pathohistologic proﬁles in
glioblastoma,” Cancer Genetics and Cytogenetics, vol. 166, no. 1, pp. 46–55, 2006.
[40] Z. Huang, L. Cheng, O. A. Guryanova, Q. Wu, and S. Bao, “Cancer stem cells in glioblastoma—molecular
signaling and therapeutic targeting,” Protein Cell, vol. 1, pp. 638–655, 2010.
[41] R. Galli, E. Binda, U. Orfanelliet al.,“Isolationand characterizationof tumorigenic,stem-likeneuralprecursors
from human glioblastoma,” Cancer Research, vol. 64, no. 19, pp. 7011–7021,2004.
[42] S. K. Singh, C. Hawkins, I. D. Clarke et al., “Identiﬁcation of human brain tumour initiating cells,” Nature,v o l .
432, no. 7015, pp. 396–401, 2004.
[43] R. J. GilbertsonandJ. N. Rich, “Makinga tumour’sbed:glioblastomastem cellsand thevascularniche,”Nature
Reviews Cancer, vol. 7, no. 10, pp. 733–736, 2007.
[44] C. Calabrese, H. Poppleton, M. Kocak et al., “A perivascular niche for brain tumor stem cells,” Cancer Cell,
vol. 11, no. 1, pp. 69–82, 2007.
[45] J. M. Heddleston, Z. Li, J. D. Lathia, S. Bao, A. B. Hjelmeland, and J. N. Rich, “Hypoxia inducible factors in
cancer stem cells,” The British Journal of Cancer, vol. 102, no. 5, pp. 789–795, 2010.
[46] J. M. Heddleston, Z. Li, R. E. McLendon, A. B. Hjelmeland, and J. N. Rich, “The hypoxic microenvironment
maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype,” Cell
Cycle, vol. 8, no. 20, pp. 3274–3284,2009.
[47] Z. Li, S. Bao, Q. Wu et al., “Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells,”
Cancer Cell, vol. 15, no. 6, pp. 501–513, 2009.
[48] S. G. M. Piccirillo, R. Combi, L. Cajola et al., “Distinct pools of cancer stem-like cells coexist within human
glioblastomas and display differenttumorigenicityand independentgenomic evolution,”Oncogene, vol. 28, no.
15, pp. 1807–1811,2009.
[49] A. F. Olumi,G. D.Grossfeld,S.W. Hayward,P.R. Carroll,T.D. Tlsty,andG. R. Cunha,“Carcinoma-associated
ﬁbroblasts direct tumor progression of initiated human prostatic epithelium,” Cancer Research, vol. 59, no. 19,
pp. 5002–5011,1999.
[50] J. B. Sneddon,H. H. Zhen, K. Montgomeryet al., “Bone morphogeneticprotein antagonistgremlin1 is wideley
expressed by cancer-associated stromal cells and can promote tumor cell proliferation,” Proceedings of the
National Academy of Sciences of the United States of America, vol. 103, no. 40, pp. 14842–14847,2006.
[51] F. De Toni, C. Racaud-Sultan, G. Chicanne et al., “A crosstalk between the Wnt and the adhesion-dependent
signaling pathways governs the chemosensitivity of acute myeloid leukemia,” Oncogene, vol. 25, no. 22, pp.
3113–3122,2006.
[52] L. Jin, K. J. Hope,Q. Zhai,F. Smadja-Joffe,andJ. E. Dick, “Targetingof CD44 eradicateshumanacute myeloid
leukemic stem cells,” Nature Medicine, vol. 12, no. 10, pp. 1167–1174, 2006.
[53] D. S. Krause, K. Lazarides, U. H. von Andrian, and R. A. Van Etten, “Requirement for CD44 in homing and
engraftment of BCR-ABL-expressing leukemic stem cells,” Nature Medicine, vol. 12, no. 10, pp. 1175–1180,
2006.
[54] D. Hambardzumyan, O. J. Becher, M. K. Rosenblum, P. P. Pandolﬁ, K. Manova-Todorova, and E. C. Holland,
“PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in
medulloblastoma in vivo,” Genes and Development, vol. 22, no. 4, pp. 436–448, 2008.
[55] S. Indraccolo, S. Minuzzo, M. Masiero et al., “Cross-talk between tumor and endothelial cells involving the
Notch3-DII4 interaction marks escape from tumor dormancy,”Cancer Research, vol. 69, no. 4, pp. 1314–1323,
2009.
[56] F. Pistollato, E. Rampazzo, L. Persano et al., “Interaction of hypoxia-inducible factor-1α and Notch signaling
regulates medulloblastoma precursor proliferation and fate,” Stem Cells, vol. 28, no. 11, pp. 1918–1929,2010.
1838TheScientiﬁcWorldJOURNAL (2011) 11, 1829–1841
[57] C. Leventhal, S. Raﬁi, D. Raﬁi, A. Shahar, and S. A. Goldman, “Endothelial trophic support of neuronal
production and recruitment from the adult mammalian subependyma,” Molecular and Cellular Neurosciences,
vol. 13, no. 6, pp. 450–464, 1999.
[58] C. Ramirez-Castillejo, F. Sanchez-Sanchez, C. Andreu-Agullo et al., “Pigment epithelium-derived factor is a
niche signal for neural stem cell renewal,” Nature Neuroscience, vol. 9, pp. 331–339, 2006.
[59] B. Le Bras, M. J. Barallobre, J. Homman-Ludiye et al., “VEGF-C is a trophic factor for neural progenitors in
the vertebrate embryonic brain,” Nature Neuroscience, vol. 9, no. 3, pp. 340–348, 2006.
[60] N. Charles, T. Ozawa, M. Squatrito et al., “Perivascular nitric oxide activates notch signaling and promotes
stem-like character in PDGF-induced glioma cells,” Cell Stem Cell, vol. 6, no. 2, pp. 141–152, 2010.
[61] S. Takano, T. Yamashita, and O. Ohneda, “Molecular therapeutic targets for glioma angiogenesis,” Journal of
Oncology, Article ID 351908, 2010.
[62] D. C. Chow, L. A. Wenning, W. M. Miller, and E. T. Papoutsakis, “Modeling pO2 distributions in the bone
marrow hematopoietic compartment. II. Modiﬁed Kroghian models,” Biophysical Journal, vol. 81, no. 2, pp.
685–696, 2001.
[63] D. C. Chow, L. A. Wenning, W. M. Miller, and E. T. Papoutsakis, “Modeling pO2 distributions in the bone
marrow hematopoieticcompartment.I. Krogh’smodel,”BiophysicalJournal,vol. 81, no. 2, pp. 675–684,2001.
[64] M. G. Cipolleschi, P. D. Sbarba, and M. Olivotto, “The role of hypoxia in the maintenance of hematopoietic
stem cells,” Blood, vol. 82, no. 7, pp. 2031–2037,1993.
[65] K. Parmar, P. Mauch, J. A. Vergilio, R. Sackstein, and J. D. Down, “Distribution of hematopoietic stem cells
in the bone marrow according to regional hypoxia,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 104, no. 13, pp. 5431–5436,2007.
[66] B. Annabi, Y. T. Lee, S. Turcotte et al., “Hypoxia promotesmurine bone-marrow-derivedstromal cell migration
and tube formation,” Stem Cells, vol. 21, no. 3, pp. 337–347, 2003.
[67] K. L. Covello, J. Kehler, H. Yu et al., “HIF-2α regulates Oct-4: effects of hypoxia on stem cell function,
embryonic development, and tumor growth,” Genes and Development, vol. 20, no. 5, pp. 557–570, 2006.
[68] H. Iwasaki and T. Suda, “Cancer stem cells and their niche,” Cancer Science, vol. 100, no. 7, pp. 1166–1172,
2009.
[69] H. Li, X. Fan, and J. Houghton, “Tumor microenvironment:the role of the tumor stroma in cancer,” Journal of
Cellular Biochemistry, vol. 101, no. 4, pp. 805–815, 2007.
[70] A. Soeda,M. Park,D. Leeetal.,“HypoxiapromotesexpansionoftheCD133-positivegliomastem cellsthrough
activation of HIF-1α,” Oncogene, vol. 28, no. 45, pp. 3949–3959,2009.
[71] E. M. Hammond and A. J. Giaccia, “The role of p53 in hypoxia-induced apoptosis,” Biochemical and
Biophysical Research Communications, vol. 331, no. 3, pp. 718–725, 2005.
[72] M. Koshiji, K. K. To, S. Hammer et al., “HIF-1α induces genetic instability by transcriptionallydownregulating
MutSα expression,” Molecular Cell, vol. 17, no. 6, pp. 793–803, 2005.
[73] M. Tafani, M. Di Vito, A. Frati et al., “Pro-inﬂammatory gene expression in solid glioblastoma
microenvironment and in hypoxic stem cells from human glioblastoma,” Journal of Neuroinﬂammation,v o l .
8, p. 32, 2011.
[74] F. Pistollato, S. Abbadi, E. Rampazzo et al., “Intratumoral hypoxic gradient drives stem cells distribution and
MGMT expression in glioblastoma,” Stem Cells, vol. 28, no. 5, pp. 851–862, 2010.
[75] F. Pistollato, L. Persano, A. D. Puppa, E. Rampazzo, and G. Basso, “Isolation and expansion of regionally
deﬁned human glioblastoma cells in vitro,” Current Protocols in Stem Cell Biology, chapter 3, unit 3.4, 2011.
[76] E. E. Bar, A. Lin, V. Mahairaki, W. Matsui, and C. G. Eberhart, “Hypoxia increases the expression of stem-cell
markers and promotes clonogenicity in glioblastoma neurospheres,” The American Journal of Pathology,v o l .
177, no. 3, pp. 1491–1502,2010.
[77] J. Mazumdar, V. Dondeti, and M. C. Simon, “Hypoxia-inducible factors in stem cells and cancer,” Journal of
Cellular and Molecular Medicine, vol. 13, no. 11-12, pp. 4319–4328,2009.
[78] F. Pistollato, E. Rampazzo, S. Abbadi et al., “Molecular mechanisms of HIF-1α modulation induced by oxygen
tension and BMP2 in glioblastoma derived cells,” PLoS One, vol. 4, no. 7, Article ID e6206, 2009.
[79] B. Das, R. Tsuchida, D. Malkin, G. Koren, S. Baruchel, and H. Yeger, “Hypoxia enhances tumor stemness by
increasing the invasive and tumorigenic side population fraction,” Stem Cells, vol. 26, no. 7, pp. 1818–1830,
2008.
1839TheScientiﬁcWorldJOURNAL (2011) 11, 1829–1841
[80] A. L. Harris, “Hypoxia—a key regulatory factor in tumour growth,” Nature Reviews Cancer, vol. 2, no. 1, pp.
38–47, 2002.
[81] S. Diabira and X. Morandi, “Gliomagenesis and neural stem cells: key role of hypoxia and concept of tumor
”neo-niche”,” Medical Hypotheses, vol. 70, no. 1, pp. 96–104, 2008.
[82] S. Seidel, B. K. Garvalov, V. Wirta et al., “A hypoxic niche regulates glioblastoma stem cells through hypoxia
inducible factor 2 alpha,” Brain, vol. 133, pp. 983–995, 2010.
[83] K. Takahashi and S. Yamanaka,“Inductionof pluripotentstem cells from mouse embryonicand adult ﬁbroblast
cultures by deﬁned factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006.
[84] C. Altaner, “Glioblastoma and stem cells,” Neoplasma, vol. 55, no. 5, pp. 369–374, 2008.
[85] A.Natsume,S.Kinjo,K.Yukietal.,“Glioma-initiatingcellsandmolecularpathology:implicationsfortherapy,”
Brain Tumor Pathology, vol. 28, pp. 1–12, 2011.
[86] X. Yan, L. Ma, D. Yi et al., “A CD133-related gene expression signature identiﬁes an aggressive glioblastoma
subtype with excessive mutations,” Proceedings of the National Academy of Sciences of the United States of
America, vol. 108, pp. 1591–1596,2011.
[87] K. Nishide, Y. Nakatani, H. Kiyonari, and T. Kondo, “Glioblastoma formation from cell population depleted of
prominin1-expressingcells,” PLoS One, vol. 4, no. 8, Article ID e6869, 2009.
[88] A. T. Ogden, A. E. Waziri, R. A. Lochhead et al., “Identiﬁcation of A2B5+CD133- tumor-initiating cells in
adult human gliomas,” Neurosurgery, vol. 62, no. 2, pp. 505–514, discussion 514–505, 2008.
[89] A. Sato, K. Sakurada, T. Kumabe et al., “Association of stem cell marker CD133 expression with dissemination
of glioblastomas,” Neurosurgical Review, vol. 33, no. 2, pp. 175–183, discussion 183–174, 2010.
[90] J. Wang, P. O. Sakariassen, O. Tsinkalovsky et al., “CD133 negative glioma cells form tumors in nude rats and
give rise to CD133 positive cells,” International Journal of Cancer, vol. 122, no. 4, pp. 761–768, 2008.
[91] L. Prestegarden, A. Svendsen, J. Wang et al., “Glioma cell populations grouped by different cell type markers
drive brain tumor growth,” Cancer Research, vol. 70, no. 11, pp. 4274–4279,2010.
[92] Q. Shen, Y. Wang, E. Kokovay et al., “Adult SVZ stem cells lie in a vascular niche: a quantitative analysis of
niche cell-cell interactions,” Cell Stem Cell, vol. 3, no. 3, pp. 289–300, 2008.
[93] M. Tavazoie, L. Van der Veken, V. Silva-Vargaset al., “A specialized vascular niche for adult neural stem cells,”
Cell Stem Cell, vol. 3, no. 3, pp. 279–288, 2008.
[94] D. Zipori, “The nature of stem cells: state rather than entity,” Nature Reviews Genetics, vol. 5, no. 11, pp.
873–878, 2004.
[95] A. M. Spence, M. Muzi, K. R. Swanson et al., “Regional hypoxia in glioblastoma multiforme quantiﬁed
with [18F]ﬂuoromisonidazole positron emission tomography before radiotherapy: correlation with time to
progression and survival,” Clinical Cancer Research, vol. 14, no. 9, pp. 2623–2630,2008.
[96] M. E. Hegi, A. C. Diserens, S. Godard et al., “Clinical trial substantiates the predictive value of
O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with
temozolomide,” Clinical Cancer Research, vol. 10, no. 6, pp. 1871–1874,2004.
[97] M. E.Hegi,L. Liu,J. G. Hermanetal., “CorrelationofO6-methylguaninemethyltransferase(MGMT)promoter
methylationwith clinical outcomesin glioblastomaandclinical strategiesto modulateMGMT activity,”Journal
of Clinical Oncology, vol. 26, no. 25, pp. 4189–4199,2008.
[98] M. Labussiere, X. W. Wang, A. Idbaih, F. Ducray, and M. Sanson, “Prognostic markers in gliomas,” Future
Oncology, vol. 6, no. 5, pp. 733–739, 2010.
[99] J. T. Huse, H. S. Phillips, and C. W. Brennan, “Molecular subclassiﬁcation of diffuse gliomas: seeing order in
the chaos,” Glia, vol. 59, pp. 1190–1199,2011.
[100] L.Karayan-Tapon,V.Quillien,J.Guilhotetal.,“PrognosticvalueofO6-methylguanine-DNAmethyltransferase
status in glioblastoma patients, assessed by ﬁve different methods,” Journal of Neuro-Oncology, vol. 97, no. 3,
pp. 311–322, 2010.
[101] D. A. Reardon, E. Galanis, J. F. DeGroot et al., “Clinical trial end points for high-grade glioma: the evolving
landscape,” Journal of Neuro-Oncology, vol. 13, pp. 353–361, 2011.
[102] V. T. Cao, T. Y. Jung, S. Jung et al., “The correlation and prognostic signiﬁcance of MGMT promoter
methylation and MGMT protein in glioblastomas,” Neurosurgery, vol. 65, no. 5, pp. 866–875, 2009.
[103] L. Cheng, S. Bao, and J. N. Rich, “Potential therapeutic implications of cancer stem cells in glioblastoma,”
Biochemical Pharmacology, vol. 80, no. 5, pp. 654–665, 2010.
1840TheScientiﬁcWorldJOURNAL (2011) 11, 1829–1841
[104] S. Coma, A. Shimizu, and M. Klagsbrun, “Hypoxia induces tumor and endothelial cell migration in
a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor
neuropilin 2,” Cell Adhesion & Migration, vol. 5, pp. 266–275, 2011.
[105] P. A. Cronin, J. H. Wang, and H. P. Redmond, “Hypoxia increases the metastatic ability of breast cancer cells
via upregulation of CXCR4,” BMC Cancer, vol. 10, article 225, 2010.
[106] E. Piovan,V. Tosello, S. Indraccoloet al., “Differentialregulationof hypoxia-inducedCXCR4 triggeringduring
B-cell development and lymphomagenesis,” Cancer Research, vol. 67, no. 18, pp. 8605–8614,2007.
[107] A. Quinones-Hinojosa, N. Sanai, O. Gonzalez-Perez, and J. M. Garcia-Verdugo, “The human brain
subventricular zone: stem cells in this niche and its organization,” Neurosurgery Clinics of North America,
vol. 18, pp. 15–20, 2007.
[108] S. H. Lin and L. R. Kleinberg, “Carmustine wafers: localized delivery of chemotherapeutic agents in CNS
malignancies,” Expert Review of Anticancer Therapy, vol. 8, no. 3, pp. 343–359, 2008.
[109] A. B. Fleming and W. M. Saltzman, “Pharmacokineticsof the carmustine implant,” Clinical Pharmacokinetics,
vol. 41, no. 6, pp. 403–419, 2002.
This article should be cited as follows:
Luca Persano, Elena Rampazzo, Alessandro Della Puppa, Francesca Pistollato, and Giuseppe Basso, “The
Three-Layer Concentric Model of Glioblastoma: Cancer Stem Cells, Microenvironmental Regulation, and
Therapeutic Implications,” TheScientiﬁcWorldJOURNAL,vol. 11, pp. 1829–1841, 2011.
1841